Evidence map›Paper›PMID 32066675›Full record

ArticleTranslational psychiatry2020

Comprehensive analysis of a novel mouse model of the 22q11.2 deletion syndrome: a model with the most common 3.0-Mb deletion at the human 22q11.2 locus.

Ryo Saito, Michinori Koebis, Taku Nagai, Kimiko Shimizu, Jingzhu Liao, Bolati Wulaer, Yuki Sugaya, Kenichiro Nagahama, Naofumi Uesaka, Itaru Kushima and 9 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Ryo SaitoLaboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Michinori KoebisLaboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Taku NagaiDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0001-5050-7748
Kimiko ShimizuDepartment of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4943-2552
Jingzhu LiaoDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Bolati WulaerDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yuki SugayaDepartment of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenichiro NagahamaDepartment of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naofumi UesakaDepartment of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Daisuke MoriDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-9072-2546
Kazuaki MaruyamaDepartment of Physiological Chemistry and Metabolism, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kazuki NakaoLaboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroki KuriharaDepartment of Physiological Chemistry and Metabolism, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyofumi YamadaDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Masanobu KanoDepartment of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0725-3292
Yoshitaka FukadaDepartment of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-7360-4898
Atsu AibaLaboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. aiba@m.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-8192-0778
The University of Tokyo · JPNagoya University Hospital · JPNagoya University · JP

Funding

Japan Agency for Medical Research and Development (AMED) 18dm0207004h0005MEXT | Japan Society for the Promotion of Science (JSPS) 17H06096
6 · The paper itself

Abstract

The 22q11.2 deletion syndrome (22q11.2DS) is associated with an increased risk for psychiatric disorders. Although most of the 22q11.2DS patients have a 3.0-Mb deletion, existing mouse models only mimic a minor mutation of 22q11.2DS, a 1.5-Mb deletion. The role of the genes existing outside the 1.5-Mb deletion in psychiatric symptoms of 22q11.2DS is unclear. In this study, we generated a mouse model that reproduced the 3.0-Mb deletion of the 22q11.2DS (Del(3.0 Mb)/ +) using the CRISPR/Cas9 system. Ethological and physiological phenotypes of adult male mutants were comprehensively evaluated by visual-evoked potentials, circadian behavioral rhythm, and a series of behavioral tests, such as measurement of locomotor activity, prepulse inhibition, fear-conditioning memory, and visual discrimination learning. As a result, Del(3.0 Mb)/ + mice showed reduction of auditory prepulse inhibition and attenuated cue-dependent fear memory, which is consistent with the phenotypes of existing 22q11.2DS models. In addition, Del(3.0 Mb)/ + mice displayed an impaired early visual processing that is commonly seen in patients with schizophrenia. Meanwhile, unlike the existing models, Del(3.0 Mb)/ + mice exhibited hypoactivity over several behavioral tests, possibly reflecting the fatigability of 22q11.2DS patients. Lastly, Del(3.0 Mb)/ + mice displayed a faster adaptation to experimental jet lag as compared with wild-type mice. Our results support the validity of Del(3.0 Mb)/ + mice as a schizophrenia animal model and suggest that our mouse model is a useful resource to understand pathogenic mechanisms of schizophrenia and other psychiatric disorders associated with 22q11.2DS.

Indexed as

DiGeorge SyndromeSchizophreniaAdultAnimalsDisease Models, AnimalHumansMaleMemoryMicePhenotype

Identifiers

PMID32066675
PMCPMC7026107
OpenAlexW3004572119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.